Viral vector provider opens new UK headquarters in Edinburgh

VectorBuilder Edinburgh office

Gene delivery technologies company VectorBuilder has opened a new office in Edinburgh, hoping to bolster its presence in the United Kingdom.

The new location is part of Edinburgh Technopole, a Pioneer Group in Midlothian Science Zone.

“When it comes to published scientific research, the UK is ranked third in the world with nearly 200,000 citable publications in 2020. With VectorBuilder’s UK team rapidly growing and an organisational commitment to scientific research, it made sense for VectorBuilder to open an office in the country,” said Christina McClure, Associate Sales Director of Europe, UK, and Scandinavia of VectorBuilder.

The company previously participated in the first human trial of a gene therapy drug candidate for Menkes disease, and recently partnered with Stand Up Therapeutics to produce and supply gene therapy products for the treatment of paralysis.

“As a provider of AAV viral vectors, VectorBuilder has played a crucial role in freeing up our time to focus more on research by providing large quantities of high-quality viral vector for in vivo applications,” said Martin Madill, Senior Scientist at Purespring Therapeutics.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free